Sofosbuvir / Velpatasvir / VoxilaprevirBrand Name: Vosevi Other Names: SOF / VEL / VOX Drug Class: Opportunistic Infections and Coinfections
What is Vosevi?
Vosevi is anprescription medicine approved by the U.S. (FDA) for the treatment of chronic (lasting a long time) (HCV), including in people with and without a certain type of damage called compensated cirrhosis.
HCV is an opportunistic infections (OIs) of HIV. An OI is an infection that occurs more frequently or is more severe in people with weakened immune systems—such as people with HIV—than in people with healthy immune systems.To learn more about OIs, read the What is an Opportunistic Infection? fact sheet.
To learn how HIV and HCV are connected, read the AIDSinfo HIV and Hepatitis C fact sheet. The fact sheet includes information about how HCV is spread, symptoms of HCV, and treatment options.
How is Vosevi used in people with HIV?
The Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents include recommendations on the HIV-related use of Vosevi to treat HCV.
Using a medicine as indicated on the medicine label is calledThe guidelines include recommendations on the following uses of Vosevi: ; using the medicine in a different way is called . Off-label use, for example, can include using a drug for a different disease or medical condition. Good medical practice and the best interests of a patient sometimes require that a medicine be used off-label.
- On-label use: treatment of chronic HCV
- Off-label use: treatment of acute HCV
This may not include all of the HIV-related uses of Vosevi recommended in the guidelines. Some recommended uses, such as uses in certain rare circumstances, may have been omitted.
What should I tell my health care provider before taking Vosevi?
Before taking Vosevi, tell your health care provider:
- If you are allergic to any of the medicines in Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) or any other medicines.
- About any medical conditions you have or have had.
- About anything that could affect your ability to take medicines, such as difficulty swallowing or remembering to take tablets.
- If you are pregnant or plan to become pregnant. Whether Vosevi can harm an unborn baby is unknown. Talk to your health care provider about possible risks with taking Vosevi when pregnant.
- If you are breastfeeding or plan to breastfeed. Do not breastfeed if you have HIV.
- About other prescription and nonprescription medicines, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Vosevi may affect the way other medicines or products work, and other medicines or products may affect how Vosevi works. Ask your health care provider if there are interactions between Vosevi and the other medicines you take.
Ask your health care provider about possible side effects from Vosevi. Your health care provider will tell you what to do if you have side effects.
How should I take Vosevi?
Take Vosevi according to your health care provider’s instructions. Your health care provider will tell you how much Vosevi to take and when to take it. Before you start Vosevi and each time you get a refill, read any printed information that comes with your medicine.
How should Vosevi be stored?
- Store Vosevi at or below 86°F (30°C).
- Keep Vosevi in its original container until you are ready to take it.
- Do not use Vosevi if the original seal over the bottle opening is broken or missing.
- Throw away Vosevi that is no longer needed or expired (out of date). Follow FDA guidelines on how to safely dispose of unused medicine.
- Keep Vosevi and all medicines out of reach of children.
Where can I find more information about Vosevi?
More information about Vosevi is available:
- Recommendations on the HIV-related uses of Vosevi, from the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, prepared by the , the , and the HIV Medicine Association of the Diseases Society of America.
- Vosevi-related research studies, from the AIDSinfo database of study summaries.
The above Patient Version drug summary is based on the following FDA label(s): Tablet, film-coated.
Last Reviewed: July 20, 2018